Patents by Inventor Stephan Schilling

Stephan Schilling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11045533
    Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: June 29, 2021
    Inventors: Martin Kleinschmidt, Jens-Ulrich Rahfeld, Anke Piechotta, Stephan Schilling, Stephen Gillies
  • Publication number: 20210032315
    Abstract: The invention relates to humanized and de-immunized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of monoclonal antibodies of the invention to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the antibodies of the invention.
    Type: Application
    Filed: January 29, 2019
    Publication date: February 4, 2021
    Inventors: Jens-Ulrich RAHFELD, Stephen Gillies, Thore HETTMANN, Stephan SCHILLING, Martin KLEINSCHMIDT
  • Publication number: 20200264197
    Abstract: The present invention can be included in the field of medicine. Specifically, the present invention provides antibodies and antigen-binding fragments thereof which can bind isoAsp7 amyloid ? (A?) and a pharmaceutical composition comprising the antibodies or antigen-binding fragments thereof. IsoAsp7 A? can be found in plaques of Alzheimer's patients and is thus a suitable target for the treatment and/or prevention of A?-related diseases such as Alzheimer's disease. Thus, the antibodies, antigen-binding fragments thereof and the pharmaceutical composition comprising either can be used to treat and/or prevent neurodegenerative diseases. Further, the present invention provides hybridoma cell lines, the use of the antibodies or antigen-binding fragments thereof for the diagnosis and/or prognosis of a neurodegenerative disease and a method for detecting isoAsp7 A? in an isolated sample.
    Type: Application
    Filed: July 17, 2018
    Publication date: August 20, 2020
    Inventors: Anke PIECHOTTA, Kathrin GNOTH, Holger CYNIS, Jens-Ulrich RAHFELD, Stephan SCHILLING, Hans-Ulrich DEMUTH
  • Publication number: 20200138922
    Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.
    Type: Application
    Filed: January 16, 2020
    Publication date: May 7, 2020
    Inventors: Martin Kleinschmidt, Jens-Ulrich Rahfeld, Anke Piechotta, Stephan Schilling, Stephen Gillies
  • Patent number: 10603367
    Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: March 31, 2020
    Assignee: Probiodrug AG
    Inventors: Martin Kleinschmidt, Jens-Ulrich Rahfeld, Anke Piechotta, Stephan Schilling, Stephen Gillies
  • Publication number: 20180228825
    Abstract: The invention relates to the use of a compound of formula (I), or a composition containing the compound, as glutaminyl cyclase (QC) inhibitor and to methods of preparation.
    Type: Application
    Filed: September 15, 2016
    Publication date: August 16, 2018
    Applicants: Hochschule Anhalt, Leibniz-Institut Für Pflanzenbiochemie (IPB)
    Inventors: Stephanie Hielscher-Michael, Carola Griehl, Hans-Ulrich Demuth, Stephan Schilling, Ludger Wessjohann, Norbert Arnold
  • Publication number: 20180140689
    Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.
    Type: Application
    Filed: January 10, 2018
    Publication date: May 24, 2018
    Inventors: Martin Kleinschmidt, Jens-Ulrich Rahfeld, Anke Piechotta, Stephan Schilling, Steven Gillies
  • Publication number: 20170363645
    Abstract: The invention relates to a highly sensitive method for the detection of pGlu-Abeta (pGlu-A?) peptides and the use of this method in the diagnosis of neurodegenerative diseases, such as Alzheimer's disease and Mild Cognitive Impairment. The invention further concerns a novel method for monitoring the effectiveness of a treatment of neurode-generative diseases by monitoring changes in the level of pGlu-A? peptides.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 21, 2017
    Inventors: Martin Kleinschmidt, Torsten Hoffmann, Jens-Ulrich Rahfeld, Stephan Schilling, Beena Punnamoottil, Michael Adler
  • Patent number: 9734326
    Abstract: A protection unit of an interrupt stack accessible by a CPU controlled by one software program, for storing and removing stack frame(s), the stack protection unit being coupleable to the stack and the CPU, comprising: a processor coupled to a first and a second address register; wherein, when a first stack frame is stored onto the stack and the execution of the software program is suspended by the CPU, responsive to one or more occurring hardware IRQs; the processing unit is adapted to set one access rule based on the first and second address registers, preventing: the occurring ISR to be serviced, from accessing a hardware-protected region of the stack, comprising at least the first stack frame and at least one stack frame associated with one or more suspended IRQs. A processor, a method and a computer program are also claimed.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: August 15, 2017
    Assignee: NXP USA, Inc.
    Inventors: Dirk Heisswolf, Andreas Ralph Pachl, Alexander Stephan Schilling
  • Patent number: 9676843
    Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: June 13, 2017
    Assignee: PROBIODRUG AG
    Inventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gnoth, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer
  • Patent number: 9657089
    Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: May 23, 2017
    Assignee: PROBIODRUG AG
    Inventors: Martin Kleinschmidt, Stephan Schilling, Jens-Ulrich Rahfeld, Kristin Ebermann, Hans-Ulrich Demuth
  • Publication number: 20170097365
    Abstract: A method for predicting, diagnosing and prognosticating a neurodegenerative disease, such as Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and neurodegeneration in Down's syndrome (NDS) using glutaminyl cyclase (QC) as a diagnostic/prognostic indicator. The use of antibodies binding to QC and kits for performing said diagnostic method are also provided.
    Type: Application
    Filed: December 14, 2016
    Publication date: April 6, 2017
    Inventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Jens-Ulrich Rahfeld, Astrid Kehlen, Monique Haegele
  • Patent number: 9462793
    Abstract: The present invention provides a knock-out non-human animal, in particular a mouse carrying a Qpct knock-out mutation. The present invention additionally provides the respective cells and cell lines and methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: October 11, 2016
    Assignee: PROBIODRUG AG
    Inventors: Stephan Schilling, Torsten Hoffmann, Hans-Ulrich Demuth
  • Patent number: 9369150
    Abstract: A method for protecting a data item against unauthorized access and a data processing device is disclosed comprising a memory unit and a memory control unit to protect data items stored in the memory unit against prohibited access. Upon a write access the memory control unit forms a first data word comprising a data item and a first key; computes a first error-detection code; and stores the data item along with the first error-detection code. Upon a read access the memory control unit reads the data item and the first error-detection code; forms a second data word comprising the data item and a second key; computes a second error-detection code to the second data word; and determines a syndrome on the basis of the first error-detection code and the second error-detection code, wherein the syndrome is indicative of whether or not the first and second data words are identical.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: June 14, 2016
    Assignee: FREESCALE SEMICONDUCTOR, INC.
    Inventors: Dirk Heisswolf, Andreas Ralph Pachl, Alexander Stephan Schilling
  • Patent number: 9277737
    Abstract: A knock-out non-human animal, in particular a mouse, carrying a QPCTL knock-out mutation. Additionally, respective cells and cell lines and methods and compositions for evaluating agents that affect QPCTL, for use in compositions for the treatment of QPCTL-related diseases are disclosed.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: March 8, 2016
    Assignee: PROBIODRUG AG
    Inventors: Hans-Ulrich Demuth, Anett Stephan, Birgit Koch, Holger Cynis, Stephan Schilling, Reinhard Sedlmeier, Sigrid Graubner
  • Publication number: 20160053001
    Abstract: Novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
    Type: Application
    Filed: September 3, 2015
    Publication date: February 25, 2016
    Inventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gans, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer
  • Publication number: 20160036463
    Abstract: A method for protecting a data item against unauthorized access and a data processing device is disclosed comprising a memory unit and a memory control unit to protect data items stored in the memory unit against prohibited access. Upon a write access the memory control unit forms a first data word comprising a data item and a first key; computes a first error-detection code; and stores the data item along with the first error-detection code. Upon a read access the memory control unit reads the data item and the first error-detection code; forms a second data word comprising the data item and a second key; computes a second error-detection code to the second data word; and determines a syndrome on the basis of the first error-detection code and the second error-detection code, wherein the syndrome is indicative of whether or not the first and second data words are identical.
    Type: Application
    Filed: July 29, 2014
    Publication date: February 4, 2016
    Applicant: FREESCALE SEMICONDUCTOR, INC.
    Inventors: DIRK HEISSWOLF, ANDREAS RALPH PACHL, ALEXANDER STEPHAN SCHILLING
  • Publication number: 20150361167
    Abstract: Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE).
    Type: Application
    Filed: August 31, 2015
    Publication date: December 17, 2015
    Inventors: Holger Cynis, Hans-Ulrich Demuth, Jens-Ulrich Rahfeld, Stephan Schilling, Kathrin Gans, Sonja Kampfer
  • Patent number: 9156907
    Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular, Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: October 13, 2015
    Assignee: PROBIODRUG AG
    Inventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gans, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer
  • Patent number: 9157918
    Abstract: Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE).
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: October 13, 2015
    Assignee: PROBIODRUG AG
    Inventors: Holger Cynis, Hans-Ulrich Demuth, Jens-Ulrich Rahfeld, Stephan Schilling, Kathrin Gans, Sonja Kampfer